drugset / Trial / NCT01160822

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

NCT01160822

Phase 2 Completed 169 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to determine whether, in patients with mild to moderate knee osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.

Timeline

Start
2010-04
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 150 mg Other
Subject Canakinumab Monoclonal antibody 300 mg Other
Subject Canakinumab Monoclonal antibody 600 mg Other
Comparator Naproxen Small molecule 500 mg Oral

Indications